Brokerages Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) PT at $9.70

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $9.70.

Several research analysts recently commented on XFOR shares. Weiss Ratings raised X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday. Leerink Partners assumed coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $12.00 price objective for the company. Finally, Wells Fargo & Company started coverage on shares of X4 Pharmaceuticals in a research note on Friday, July 10th. They set an “overweight” rating and a $11.00 target price on the stock.

X4 Pharmaceuticals Trading Down 0.5%

Shares of NASDAQ XFOR opened at $3.98 on Friday. The company has a current ratio of 10.18, a quick ratio of 9.98 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $375.39 million, a PE ratio of -0.88 and a beta of 0.35. X4 Pharmaceuticals has a twelve month low of $1.35 and a twelve month high of $4.83. The stock has a fifty day simple moving average of $4.01 and a 200-day simple moving average of $3.93.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its earnings results on Wednesday, May 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. The company had revenue of $2.71 million during the quarter, compared to the consensus estimate of $3.20 million. X4 Pharmaceuticals had a negative return on equity of 94.90% and a negative net margin of 1,106.30%. On average, equities analysts forecast that X4 Pharmaceuticals will post -0.77 earnings per share for the current year.

Insider Buying and Selling

In other X4 Pharmaceuticals news, CFO David Kirske sold 8,543 shares of the stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total value of $36,393.18. Following the sale, the chief financial officer directly owned 167,750 shares of the company’s stock, valued at approximately $714,615. This represents a 4.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.13% of the stock is owned by company insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of XFOR. Pettinga Financial Advisors LLC acquired a new position in shares of X4 Pharmaceuticals during the second quarter worth $47,000. Perceptive Advisors LLC increased its holdings in X4 Pharmaceuticals by 6.7% in the first quarter. Perceptive Advisors LLC now owns 6,737,648 shares of the company’s stock valued at $27,826,000 after buying an additional 423,196 shares during the last quarter. Bank of America Corp DE raised its stake in X4 Pharmaceuticals by 321.3% in the first quarter. Bank of America Corp DE now owns 150,676 shares of the company’s stock valued at $622,000 after buying an additional 114,915 shares in the last quarter. SummitTX Capital L.P. acquired a new stake in X4 Pharmaceuticals in the first quarter valued at $46,000. Finally, Virtu Financial LLC purchased a new stake in X4 Pharmaceuticals during the 4th quarter worth about $90,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.